Skip to main content

Farrell Michael J.'s Form 4 filing

Resmed Inc (RMD) · filed Jan 8, 2026

Accession no.
0000943819-26-000003
Filed
Jan 8, 2026
Trade date
Jan 7, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.24M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Farrell Michael J.CIK 0001485164Director, Officer (Chairman and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 7, 2026ResMed Common StockMOption exerciseAcquired+4,991$146.34+$730,382.94471,214Direct
Jan 7, 2026ResMed Common StockSSaleDisposed−4,991$248.46F2−$1,240,063.86466,223Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 7, 2026ResMed Common StockMOption exerciseDisposed−4,991$0.00$049,912Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $246.801 - $249.969. The price reported above reflects the weighted average sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)